Ask me later
Ask me later
How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Thanks again for rating us!
Immunicum: MERECA data maturing in a positive direction
Research Note
2020-02-07
10:22
Yesterday’s ASCO SITC presentation provided a 24 months follow-up of the MERECA trial, and our overall impression of the new data is positive, supporting the benefit of adding ilixadencel to sunitinib. With growing confidence in ilixadencel, we are now raising our base case to SEK 17 (14). However, the share price is lower in early trading, suggesting high expectations from investors.
KP
Klas Palin
Disclosures and disclaimers